Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

19.01.2026

1 Am J Surg Pathol
2 BJU Int
1 BMC Urol
1 Br J Cancer
2 Cancer Res
3 Eur Radiol
1 Eur Urol
2 Hum Pathol
2 Int J Radiat Oncol Biol Phys
5 Int J Urol
2 J Clin Oncol
1 J Magn Reson Imaging
2 J Natl Cancer Inst
3 J Urol
4 JAMA
1 Nat Rev Urol
1 Prostate
1 Radiol Imaging Cancer
1 Urology


    Am J Surg Pathol

  1. SHI H, Wang Y, Miyamoto H
    Intraductal Carcinoma of the Prostate With a Solid Nest Pattern May Be More Aggressive Than Gleason Grade 5 Conventional Prostatic Adenocarcinoma.
    Am J Surg Pathol. 2026;50:156-162.
    >> Share


    BJU Int

  2. ZAURITO P, Garmo H, Gedeborg R, Alhberg M, et al
    Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer: a population-based study.
    BJU Int. 2026 Jan 15. doi: 10.1111/bju.70148.
    >> Share

  3. BERGEROT PG, Bergerot CD, Schmitz KH, Pal S, et al
    Enhancing quality of life in patients with prostate cancer through a remote exercise programme.
    BJU Int. 2026 Jan 16. doi: 10.1111/bju.70152.
    >> Share


    BMC Urol

  4. KACAN T, Demir DO, Yildiz AK, Gokkurt Y, et al
    Can the systemic immune-inflammation index be used to differentiate benign and malignant pathologies before transrectal ultrasound-guided prostate biopsy?
    BMC Urol. 2025;26:5.
    >> Share


    Br J Cancer

  5. FULLER H, Agasaro OP, Guevara JM, Darst BF, et al
    Pre-diagnostic circulating untargeted metabolomics and risk of overall and clinically significant prostate cancer: a systematic review and meta-analysis.
    Br J Cancer. 2026 Jan 10. doi: 10.1038/s41416-025-03312.
    >> Share


    Cancer Res

  6. THIENGER P, Paassen I, Yao X, Rubin PD, et al
    A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules.
    Cancer Res. 2026 Jan 14. doi: 10.1158/0008-5472.CAN-25-2928.
    >> Share

  7. GULLA S, Sharma T, Gardner E, Li C, et al
    MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate Cancer.
    Cancer Res. 2026 Jan 13. doi: 10.1158/0008-5472.CAN-25-1720.
    >> Share


    Eur Radiol

  8. KASS PEREL T, Sussman MS, Ghai S
    Expanding the boundaries: rethinking ablation coverage in focal therapy for prostate cancer.
    Eur Radiol. 2026 Jan 16. doi: 10.1007/s00330-025-12245.
    >> Share

  9. SMITH H, Stavrinides V, Giganti F, Moore CM, et al
    Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
    Eur Radiol. 2026 Jan 16. doi: 10.1007/s00330-025-12248.
    >> Share

  10. BITTON RR, Vertosick E, Khandwala Y, Korol G, et al
    Optimizing prostate cancer treatment with MR-guided focused ultrasound: the role of expanded ablation-to-lesion volume ratio.
    Eur Radiol. 2026 Jan 16. doi: 10.1007/s00330-025-12217.
    >> Share


    Eur Urol

  11. BENESOVA-SCHAFER M, Haberkorn U, Babich JW
    The Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for Prostate Cancer.
    Eur Urol. 2026 Jan 14:S0302-2838(26)00003-5. doi: 10.1016/j.eururo.2026.
    >> Share


    Hum Pathol

  12. WANG Y, Miyamoto H
    Quantitative assessment of cribriform intraductal carcinoma of the prostate is useful for risk stratification after radical prostatectomy.
    Hum Pathol. 2026;167:106008.
    >> Share

  13. TEKIN B, Datta L, Zargham R, Sukov WR, et al
    Sarcomatoid carcinoma of the prostate - A single institution experience with emphasis on molecular genetic findings.
    Hum Pathol. 2026;167:105988.
    >> Share


    Int J Radiat Oncol Biol Phys

  14. YASAR B, Suh YE, Chapman E, Nicholls L, et al
    2-year outcomes of the SPARC phase II trial: Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2026 Jan 11:S0360-3016(26)00019.
    >> Share

  15. VAN VLIET C, Tetar SU, Bohoudi O, Cobussen P, et al
    Long-term outcomes of Stereotactic MRI-guided adaptive radiotherapy (SMART) for prostate cancer: Results from a real world large patient cohort.
    Int J Radiat Oncol Biol Phys. 2026 Jan 14:S0360-3016(26)00065.
    >> Share


    Int J Urol

  16. MASUDA N, Hazama T, Hosomi T, Imai K, et al
    Technique Selection for Robot-Assisted Radical Prostatectomy: A Multi-Institutional Survey in Japan.
    Int J Urol. 2026;33:e70347.
    >> Share

  17. UENO Y
    Editorial Comment on "The Evolution of Prostate Multiparametric MRI and Its Application in Prostate Cancer Clinical Management".
    Int J Urol. 2026;33:e70353.
    >> Share

  18. KAR F
    Editorial Comment on (Abiraterone Acetate Triggers ER Stress-Mediated Androgen Receptor Suppression via PERK/ATF4/CHOP Signaling in Prostate Cancer).
    Int J Urol. 2026;33:e70352.
    >> Share

  19. MASSOUH K, Leucht K, Leistritz L, Grimm MO, et al
    Retrospective Analysis of Vesicourethral-Anastomosis Stricture/Urethral Stricture After Robotic-Assisted Laparoscopic Radical Prostatectomy With and Without Radiotherapy.
    Int J Urol. 2026;33:e70339.
    >> Share

  20. ALKAN VURGUN N, Sen Turk N, Vurgun S, Yagci AB, et al
    Risk-Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2-ERG, PTEN, Ki-67, and MRI-Derived Apparent Diffusion Coefficient Values.
    Int J Urol. 2026;33:e70346.
    >> Share


    J Clin Oncol

  21. ZHANG Y, Wang X, Hu H
    Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.
    J Clin Oncol. 2026 Jan 12:JCO2502107. doi: 10.1200/JCO-25-02107.
    >> Share

  22. POS FJ, Menne Guricova K, van der Voort van der Zyp JRN, Smeenk RJ, et al
    Reply to: Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.
    J Clin Oncol. 2026 Jan 12:JCO2502744. doi: 10.1200/JCO-25-02744.
    >> Share


    J Magn Reson Imaging

  23. ALLEY S, Tonneau M, Olivie D, Tempany-Afdhal CM, et al
    Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005.
    J Magn Reson Imaging. 2025 Oct 8. doi: 10.1002/jmri.70142.
    >> Share


    J Natl Cancer Inst

  24. SCUDERI S, Tin AL, Marra G, Bianchi L, et al
    Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant.
    J Natl Cancer Inst. 2026;118:76-84.
    >> Share

  25. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
    Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
    J Natl Cancer Inst. 2026;118:130-140.
    >> Share


    J Urol

  26. ZHANG F, Zhou J, Yang C, Wei S, et al
    Air Pollution, Lifestyle, and Genetic Risk: A Multidimensional Study of PM(2.5) Constituents and Prostate Cancer.
    J Urol. 2026 Jan 13:101097JU0000000000004920. doi: 10.1097/JU.0000000000004920.
    >> Share

  27. MORGENTALER A, Traish AM
    TESTOSTERONE DOES NOT DRIVE PROSTATE CANCER: PRESENTING THE NEW FRAMEWORK OF ANDROGEN ADEQUACY VERSUS INADEQUACY.
    J Urol. 2026 Jan 13:101097JU0000000000004936. doi: 10.1097/JU.0000000000004936.
    >> Share

  28. THOMPSON IM JR
    How "Floor Bias" in Gleason Grading Affects Prostate Cancer Management.
    J Urol. 2026 Jan 16:101097JU0000000000004921. doi: 10.1097/JU.0000000000004921.
    >> Share


    JAMA

  29. NG ABCD, Asif A, Kasivisvanathan V
    Biparametric vs Multiparametric MRI for Diagnosis of Prostate Cancer-Reply.
    JAMA. 2026 Jan 15. doi: 10.1001/jama.2025.22866.
    >> Share

  30. LOMBARDO R, Lorenti C, De Nunzio C
    Biparametric vs Multiparametric MRI for Diagnosis of Prostate Cancer.
    JAMA. 2026 Jan 15. doi: 10.1001/jama.2025.22869.
    >> Share

  31. PERERA MOLLIGODA ARACHCHIGE AS
    Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis.
    JAMA. 2026 Jan 15. doi: 10.1001/jama.2025.22872.
    >> Share

  32. LIN HC, Chen HT, Chang CM
    Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis.
    JAMA. 2026 Jan 15. doi: 10.1001/jama.2025.22863.
    >> Share


    Nat Rev Urol

  33. ABUSAMRA SM, Anbarasan T, Cotton DT, Ranasinha NMS, et al
    Circulating tumour cells as a window into lethality in prostate cancer.
    Nat Rev Urol. 2026 Jan 16. doi: 10.1038/s41585-025-01121.
    >> Share


    Prostate

  34. MIZOKAMI A, Matsumoto R, Miyake H, Uemura H, et al
    Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High-Risk Metastatic Hormone-Naive Prostate Cancer: Results From a 3-Year Interim Analysis of the J-ROCK Study.
    Prostate. 2026 Jan 12. doi: 10.1002/pros.70118.
    >> Share


    Radiol Imaging Cancer

  35. ALI FZ
    Quantitative PSMA PET Parameters as Prognostic Biomarkers in Patients with Metastatic Prostate Cancer Receiving Taxane-based Chemotherapy.
    Radiol Imaging Cancer. 2026;8:e259040.
    >> Share


    Urology

  36. SHACHAR E, Connor SE, Chen J, Kwan L, et al
    Fear of Cancer Recurrence among Uninsured and Underrepresented Men with Prostate Cancer.
    Urology. 2026 Jan 12:S0090-4295(26)00010-5. doi: 10.1016/j.urology.2025.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016